| variable | Person 1 | Person 2 | Person 3 | Person 4 |
|---|---|---|---|---|
| Sex | Female | Female | Male | Male |
| Age | 47 | 44 | 63 | 66 |
| Race | Hispanic | Black | White | Black |
| SBP (mmHg) | 137 | 95 | 128 | 116 |
| Statin use | No | No | No | No |
| Anticoagulant use | No | No | No | No |
| BP medication use | No | Yes | Yes | Yes |
| Currently smoking | No | Yes | No | No |
| Oral diabetes medication use | No | No | No | No |
| Total cholesterol (mg/dL) | 188 (4.9 mmol/L) | 106 (2.7 mmol/L) | 195 (5.1 mmol/L) | 122 (3.2 mmol/L) |
| HDL cholesterol (mg/dL) | 44 (1.1 mmol/L) | 36 (0.9 mmol/L) | 69 (1.8 mmol/L) | 25 (0.6 mmol/L) |
| Hemoglobin A1c (%) | 7.5 (58.5 mmol/mol) | 9.1 (76.0 mmol/mol) | 8.0 (63.9 mmol/mol) | 11.4 (101.1 mmol/mol) |
| Serum creatinine (mg/DL) | 0.6 (53.0 μmol/L) | 0.7 (61.9 μmol/L) | 1.9 (168.0 μmol/L) | 2.32 (205.1 μmol/L) |
| Urine albumin creatinine ratio (mg/g) | 54.2 | 7.6 | 68.8 | 60.0 |
| CVD history | Yes | Yes | No | Yes |
| CVD risk (10-yr risk, %) | Low | High | Low | High |
| Myocardial infarction | 8 | 12 | 7 | 56 |
| Stroke | 2 | 2 | 5 | 34 |
| Microvascular risk (10-yr risk, %) | Low | Low | High | High |
| Nephropathy | 8 | 7 | 23 | 58 |
| Retinopathy | 6 | 5 | 17 | 26 |
| Neuropathy | 7 | 7 | 16 | 23 |
| Drug ranking score (95% CI) based on network meta-analysis12* | ||||
| 1st | GLP-1RA 1.0 [0.48,1.69] |
GLP-1RA 1.0 [0.48,1.71] |
GLP-1RA 1.0 [0.47,1.70] |
GLP-1RA 1.0 [0.52,1.98] |
| 2nd | Basal insulin 0.89 [0.48,1.51] |
Basal insulin 0.89 [0.48,1.52] |
Basal insulin 0.89 [0.49,1.52] |
Basal insulin 0.86 [0.48,1.69] |
| 3rd | TZD 0.87 [0.73,1.26] |
TZD 0.87 [0.73,1.26] |
TZD 0.87 [0.73,1.26] |
TZD 0.84 [0.71,1.32] |
| 4th | SGLT-2-i 0.85 [0.62,1.35] |
SGLT-2-i 0.85 [0.62,1.35] |
SGLT-2-i 0.85 [0.62,1.35] |
SGLT-2-i 0.82 [0.59,1.44] |
| 5th | SU 0.85 [0.69,1.28] |
SU 0.85 [0.69,1.28] |
SU 0.85 [0.69,1.28] |
SU 0.82 [0.68,1.34] |
| 6th | DPP-4-I 0.75 [0.57,1.28] |
DPP-4-I 0.75 [0.56,1.29] |
DPP-4-I 0.75 [0.57,1.29] |
DPP-4-I 0.70 [0.55,1.41] |
*
Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores for other drugs are ranking scores relative the best ranking score. 95% confidence intervals were generated based on the uncertainty around the treatment effect estimates from the network meta-analysis. TZD: Thiazolidinedione; SU: Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 inhibitor